Phase 2Status unknown
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Efficacy and Safety of Ilaprazole for GERD: A Randomized,Double-Blind, Esomeprazole-Controlled,Phase2,Multicenter Trial in China
- Sponsor
- Livzon Pharmaceutical Group Inc. (Industry)
- Enrollment
- 330 planned
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- 10 mg ilaprazole; 15 mg ilaprazole; 40 mg esomeprazole
- Ages
- adults, older adults
- Registry
- NCT01107938
Full record on ClinicalTrials.gov
From the registry
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
Primary outcomes
- the proportion of patients with healed esophagitis at week 8
History
Primary completion
Started
Registered